Matthew L. Sherman
Currently, Matthew L. Sherman holds the position of Chief Medical Officer & Executive Vice President at Deciphera Pharmaceuticals, Inc. Dr. Sherman is also on the board of Pulmatrix Operating Co., Inc. and Pieris Pharmaceuticals, Inc. and Member-Alumni Council at Geisel School of Medicine.
He previously held the position of Chief Medical Officer & Executive Vice President at Acceleron Pharma, Inc., Professor at The Brigham & Women's Hospital, Inc., Chief Medical Officer & Senior Vice President at Synta Pharmaceuticals Corp., Therapeutic Area Director-Oncology at Genetics Institute LLC, Therapeutic Area Director-Oncology at Wyeth Pharmaceuticals LLC, Assistant Clinical Professor at Dana-Farber Cancer Institute, Inc., Member of The Marine Biological Laboratory and Assistant Clinical Professor at Harvard Medical School.
Matthew L. Sherman received an undergraduate degree from Massachusetts Institute of Technology and a doctorate from Dartmouth Medical School.
Transactions
| 02/16/2023 | 971 | Disposition at $15.1 per share. | 14,663 |
| 02/15/2023 | 16,488 | Award at $0 per share. | 0 |
| 01/17/2023 | 2,403 | Disposition at $21.24 per share. | 51,040 |
| 10/03/2022 | 2,587 | Disposition at $18.73 per share. | 48,455 |
| 06/16/2022 | 1,768 | Disposition at $10.75 per share. | 19,006 |
| 02/16/2022 | 984 | Disposition at $9.05 per share. | 8,906 |
| 01/18/2022 | 20,500 | Award at $0 per share. | 0 |
| 12/15/2021 | 11,100 | Award at $0 per share. | 0 |
| 10/04/2021 | 2,659 | Disposition at $33.17 per share. | 88,200 |
| 02/16/2021 | 11,100 | Award at $0 per share. | 0 |
| 02/16/2021 | 132 | Disposition at $48.87 per share. | 6,451 |
| 12/09/2020 | 207 | Derivative/Non-derivative trans. at $34.43 per share. | 7,127 |
| 11/16/2020 | 2,697 | Derivative/Non-derivative trans. at $34.43 per share. | 92,857 |
| 10/02/2020 | 2,632 | Derivative/Non-derivative trans. at $51.15 per share. | 134,627 |
| 02/18/2020 | 1,760 | Award at $0 per share. | 0 |
| 10/15/2019 | 35,000 | Award at $0 per share. | 0 |
